Back to Search
IRWIN GOLDSTEIN, M.D.
M.D.
Obstetrics & Gynecology Physician
NPI: 1366528127Individual
Specialties, Licenses & Credentials
Obstetrics & Gynecology PhysicianPrimary
Obstetrics & Gynecology
Code: 207V00000X
175807(NY)
Clinical Trials (2)
2
Linked Trials
0
Recruiting
1
With Results
Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia
NCT03568604COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA
NCT02784613COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
Research & Publications (20)
Improvements to the Vulva, Vestibule, Urethral Meatus, and Vagina in Women Treated With Ospemifene for Moderate to Severe Dyspareunia: A Prospective Vulvoscopic Pilot Study.
PMID 29678557·Sex Med·2018
8-other
Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.
PMID 28640161·Menopause·2017
2-rct
A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values.
PMID 27997350·Horm Mol Biol Clin Investig·2017
2-rct
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
PMID 26725467·Horm Mol Biol Clin Investig·2016
3-trial
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
PMID 26731686·Menopause·2016
3-trial
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
PMID 26972555·J Steroid Biochem Mol Biol·2016
8-other
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
PMID 26597311·J Sex Med·2015
2-rct
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
PMID 25734980·Menopause·2015
2-rct
Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.
PMID 23984673·Climacteric·2014
2-rct
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
PMID 24774442·J Sex Med·2014
3-trial
Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens.
PMID 23954500·J Steroid Biochem Mol Biol·2013
2-rct
One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus.
PMID 23096251·Menopause·2013
4-observational
Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
PMID 23361170·Menopause·2013
4-observational
Specializing for predicting obesity and its co-morbidities.
PMID 19041423·J Biomed Inform·2009
8-other
Three approaches to automatic assignment of ICD-9-CM codes to radiology reports.
PMID 18693842·AMIA Annu Symp Proc·2007
8-other
Prevalence of allergy symptoms and total IgE in a New York City cohort and their association with birth order.
PMID 15961954·Int Arch Allergy Immunol·2005
8-other
Use and abuse of Rigiscan in the diagnosis of erectile dysfunction.
PMID 19575775·J Sex Med·2009
8-other
Did experimental biology die? Lessons from 30 years of p53 research.
PMID 19654301·Cancer Res·2009
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 79 GRAND AVE
MASSAPEQUA, NY 11758 - Phone
- (516) 798-3376
Quick Facts
- NPI
- 1366528127
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Clinical Trials
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile